abstract: Hereditary thrombophilias can impair vascular placental functions and predispose to the birth of small-for-gestational age (SGA) babies. The placental anticoagulant protein annexin A5 (ANXA5) may contribute to this process. A functional haplotype (M2) within the ANXA5 gene is associated with fetal loss and venous thrombosis. This study investigated the prevalence of the M2 haplotype in a group of women with idiopathic SGA newborn babies. Seventy-eight women with at least one previous unexplained SGA birth and 195 controls all from Southern Italy were investigated. Hereditary thrombophilia was found in 13 (16.5%) cases and 21 (11%) controls (P , 0.05.). The M2 haplotype was found in 29% of cases (n ¼ 23) and 15% of controls [n ¼ 30; P ¼ 0.001; OR ¼ 2.3, 95% CI (1.17-4.48)]. Within the case group, 82.5% of the M2 haplotype carriers gave birth to babies with a birthweight below the 3rd percentile [P ¼ 0.01; OR ¼ 2.4, 95% CI (1.26-4.73)]. A logistic regression, corrected for age, parity and gravity showed that the M2 haplotype was independently associated with the delivery of an SGA new born [P ¼ 0.029; OR ¼ 2.6, 95% CI (1.1 -6.0)]. In conclusion, the M2 haplotype of the ANXA5 gene confers a risk of delivering SGA babies.
Introduction
It is well established that the term 'small-for-gestational age' (SGA) refers not to fetal growth but to the size of the infant at birth, whereas the term 'fetal growth restriction' (FGR) suggests a reduced growth velocity in the fetus (Iams, 2010) . The risk of perinatal morbidity and mortality is greater in SGA newborns and the risk for chronic diseases in later life, such as glucose intolerance, type 2 diabetes mellitus and cardiovascular diseases is also higher (Barker, 1997) .
Although SGA and FGR are distinct and independent adverse pregnancy outcomes, the former might represent a clinical consequence of the latter (Verkauskiene et al., 2007) and be only the tip of an iceberg.
FGR is associated with maternal factors, such as fibroma (Aydeniz et al., 1998) , alcohol intake, smoking (Jackson et al., 2007) , pregnancy-induced hypertension (Liu et al., 2008) , pre-eclampsia (Odegård et al., 2000) , malnutrition (Hendrix and Berghella, 2008) and with fetal factors, such as multiple pregnancies, chromosomal abnormalities and malformations (Tyson and Staat, 2008) . In the absence of such common causes, an impaired fetal growth is hypothesized to be due to placental insufficiency, involving any mismatch placental perfusion and fetal oxygenation. Only a third of FGR cases can be accounted for by obvious maternal, fetal and placental causes (Brodsky and Christou, 2004) , the remainder being idiopathic.
Hereditary thrombophilias, such as anti-thrombin, protein C and protein S deficiency, factor V Leiden (FVL) and prothrombin G20210A (PTm) mutations are factors predisposing to the birth of SGA babies (Martinelli et al., 2001; Roqué et al., 2004; Sabadell et al., 2010) . We previously reported that common hereditary thrombophilias and hyperhomocisteinaemia in the amniotic fluid are associated with intrauterine growth restriction (Grandone et al., 2002; Grandone et al., 2006) . However, the relationship between hereditary thrombophilia and SGA births remains controversial (Rodger et al., 2010) .
Defects in the placental anticoagulant protein annexin A5 (ANXA5) have been suggested as contributing factors to the occurrence of SGA newborns. Recently, a common haplotype (M2) within the ANXA5 has been demonstrated to be an independent risk factor for both recurrent fetal losses (Bogdanova et al., 2007; Tiscia et al., 2009) , as well as gestational hypertension and pre-eclampsia . In a luciferase reporter gene assay, this haplotype has been shown to reduce the promoter activity of the ANXA5 (Bogdanova et al., 2007) . The aim of this study was to evaluate the incidence of the M2 haplotype in a group of women with idiopathic SGA newborns.
Patients and methods

Study population
The case group included 78 women with at least one previous documented SGA newborn in the absence of any documented maternal or fetal pathology seen at the Atherosclerosis and Thrombosis Unit of the I.R.C.C.S. 'Casa Sollievo Della Sofferenza' between January 2004 and October 2009. The control group included 195 women with at least one uneventful pregnancy and in the absence of SGA newborns seen during the same time span and at the same unit. SGA was defined as a birthweight under the 10th percentile (Battaglia and Lubchenco, 1968) . All cases and controls were Caucasian women from Southern Italy. The following conditions were considered as exclusion criteria: congenital malformations or chromosomal defects, fetal infections, multiple pregnancies, essential hypertension (EH) and gestational hypertension (GH) or preeclampsia (PE). EH was defined as the occurrence of blood pressure ≥140/90 mmHg on two different occasions .4 h apart before the 20th week of gestation. GH was defined as the occurrence of blood pressure ≥140/90 mmHg on two different occasions .4 h apart in a previously normotensive woman. PE was defined as GH and significant proteinuria (≥0.3 g in a 24 h specimen). Women positive for antiphospholipid antibodies or natural anticoagulants deficiency were excluded. Information on socio-economic characteristics, lifestyle (smoking, alcohol consumption, etc.) and obstetric and reproductive history were obtained. All individuals signed informed consent; the study, after approval from the local Ethics Committees, was carried-out according to the Principles of the Declaration of Helsinki.
Sample collection, plasma-and DNA-based tests
Blood samples were collected in a 1:10 ratio in sodium citrate of 0.1 M and centrifuged at 1841g for 10 min (min) at room temperature. Plasma samples were separated and stored at 2808C until assayed for protein C, free protein S and antithrombin levels, as well as for antiphosholipid antibodies, confirmed presence of lupus anticoagulant (LA), IgG and IgM anticardiolipin antibodies (aCL), IgG and IgM anti-beta-2-glycoprotein (b 2 GPI). Platelet-free plasmas for LA testing were obtained by prefiltration through a 0.22 mm disposable filter. LA, IgG and IgM aCL, IgG and IgM b 2 GPI (QUANTA Lite TM , INOVA Diagnostics, San Diego, CA, USA), antithrombin and protein C (Berichrom w Antithrombin and Protein C amidolytic assays, Behring, Germany), and total and free protein S antigen (IMUCLONE w Protein S ELISA, American Diagnostica, Stamford, CT) were determined in all the patients. The inter-assay and intra-assay coefficients of all the variables never exceeded 8.0 and 5.0%, respectively.
Leukocyte DNA was obtained from frozen blood by the use of standard techniques. FVL and FII G20210A (PT) gene variants were tested by a TaqMan w SNP Genotyping Assay (PE; Applied Biosystems, Foster City, USA) via a Real-Time PCR System ABI PRISM w 7700 Sequence Detection System (PE; Applied Biosystems). Bogdanova et al. (2007) . When only two of the four variants (+1A/C, 27T/C) were present, the haplotype was defined as M1.
Statistical analysis
All the analyses were performed using the Statistical Package for Social Science (SPSS 6.1 for Macintosh). The difference in means was compared by a non-parametric test, whereas the significance of any difference in proportions was tested by the x 2 statistic. Allele frequencies were estimated by gene counting in cases and controls; genotypes were scored for each subject. The significance of the difference of alleles and genotypes observed between the groups was tested using the x 2 analysis, after grouping homozygous and heterozygous carriers of the FVL and PTm. x 2 (2 degree of freedom) Hardy-Weinberg equilibrium (HWE) assay was performed for all variants (Rodriguez et al., 2009 
Results
The clinical data of cases and controls are set out in Table I . As far as a smoking habit is concerned, 12/78 (15%) cases smoked 1 -10 cigarettes/day, 1 (1.3%) 10-20/day; among controls 15 (11.3%) smoked 1 -10 cigarettes/day and 7 (3.5%) 10-20/day. These differences were not statistically significant (P . 0.05). The median BMI was 22.6 (range: 17 -33) in cases and 24 (range: 18-32) in controls (P . 0.05). Sixty-two (79.5%) newborns were delivered by means of Caesarean section. Overall, a history of at least one previous fetal loss was recorded in 20 (25.5%) cases and 11 (5.5%) controls. A status of hereditary thrombophilia (Table I ) was found in 13 (16.5%; 8 FVL, 5 PTm, P . 0.05) cases and 21 controls (11%; 10 FVL, 11 PTm, P . 0.05). Sixty (77%) out of 78 cases gave birth to newborns below the 3rd percentile (31 males, 29 females), whereas the remaining 18 (23%) had a newborn with a percentile between the 10th and 3rd (7 males, 11 females). Features of the newborns according to different percentiles and SGA-related weight according to gender and gestational weeks of index-pregnancy are shown in Table II The M2 haplotype in the ANXA5 gene for SGA newborns SNP information and allelic frequencies in cases and controls are found in Table III . The presence of deviations from HWE was assayed for the four SNPs: no significant difference was found between the expected and the observed frequency for each of them (Table III) Table III. Using logistic regression analysis the M2 haplotype was independently associated with the delivery of an SGA newborn [P ¼ 0.029; OR ¼ 2.6, 95% CI (1.1 -6.0)] after correction for age, parity and gravidity.
Discussion
The ubiquitous expression of ANXA5 (Krikun et al., 1994) in synchytiotrophoblast, where the protein plays a well-known thrombomodulatory role (Ornaghi et al., 2011) , supports the idea that ANXA5 represents a functional placental-related factor. This study demonstrates a significantly higher prevalence of the M2 haplotype in a group of women with a history of idiopathic SGA babies. Women carrying the M2 haplotype have a 2-fold higher risk of giving birth to an SGA newborn. In addition, all the M2 homozygotes (no homozygote was found among controls) had a history of a severe (below the 3rd percentile) SGA. Normal fetal growth is strongly linked to the adequate transfer of solutes from maternal to fetal circulation, including oxygen and necessary nutrients. We believe that the M2 haplotype, responsible for lowering the transcriptional efficiency of the promoter, might determine a reduction in ANXA5 levels in trophoblasts, thus exposing pregnant carriers to gestational vascular complications.
Our findings confirm and extend previous data Markoff et al., 2010; Sifakis et al., 2010) . Sifakis et al. compared ANXA5 mRNA and protein levels in placentae from FGR and normal pregnancies, and found significant differences in mRNA expression (3-4 fold lower in FGR placentae) but not in protein levels. In addition, our group showed that mRNA levels in placentae are significantly lower in women carrying the M2 haplotype, independent of the presence of an obstetric complication. Thus, it is conceivable that placentae from women carrying the M2 haplotype had significantly lower mRNA levels than those from women without this haplotype. The investigation of other ANXA5 variants as risk factors for FGR/SGA has been reported. In a case-control study, a polymorphism (21C.T), known to be associated with a better translation efficiency and to an increase of protein levels (González-Conejero et al., 2002) , has been evaluated as a protective factor for FGR (Franchi et al., 2006) , although the authors failed to show a protective effect in this group of patients. More recently, the same gene variant has been shown to be in linkage disequilibrium with the M2 haplotype and in association with fetal loss in Japanese RPL population (Miyamura et al., 2011) . We suggest that the four variants within the ANXA5, inherited as the M2 haplotype, might represent an independent risk factor for otherwise unexplained SGA. Further studies on larger populations are required before considering the M2 haplotype 37 (26-42) diagnostics in the risk assessment algorithm of women who previously suffered from an idiopathic SGA.
